GenomOncology, a technology solution provider for oncology, named Brad Wertz as the new Chairman and Chief Executive Officer (CEO), who’ll assume the position from the start of year 2019. Wertz has been a founding investor and chairman of the board since the beginning, and has increased his involvement as the company has grown over the past two years.
During that time, GenomOncology has expanded its product portfolio, increased its market penetration and grown its customer base.
Wertz has a lengthy track record of scaling technology companies in rapidly emerging industries from the startup phase to large, commercial enterprises both organically and through strategic partnerships. The new CEO was was instrumental in various executive roles, in three successive transactions: Xteric Technology Group, acquired by Brulant; Brulant, acquired by Rosetta; and Rosetta, acquired by Publicis in 2011. He served as President & Chief Operating Officer (COO) of Rosetta, COO of Brulant and President and Co-Founder of Xteric Technology Group. Prior to this, he served as Vice President of Client Services for bioinformatics software company, Acero.
Manuel Glynias will remain President.
Brad Wertz said: “I am excited to partner with Manuel Glynias, founder of GenomOncology, to continue building our market-leading decision support platform for oncology. We will continue to focus on solving problems and providing next generation capabilities to rapidly advance precision oncology for our clients.”